Form 4: BioXcel CLO Javier Rodriguez Executes RSU Vesting Sale

Chief Legal Officer Javier Rodriguez sold 6,560 shares of BioXcel Therapeutics to cover tax obligations following an RSU vest.

Summary

• Javier Rodriguez, Chief Legal Officer of BioXcel Therapeutics, Inc. (BTAI), reported the vesting of 17,500 Restricted Stock Units (RSUs) on May 4, 2026.
• Following the vesting, 6,560 shares were sold on May 20, 2026, at a weighted average price of $1.084 per share.
• The sale was executed under a Rule 10b5-1 trading plan specifically to satisfy tax withholding requirements.
• The reporting person retains 26,803 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event, as the sale was pre-planned and strictly for tax purposes.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating adherence to corporate governance best practices.
• The sale was strictly for tax coverage purposes rather than a discretionary divestment of holdings.

Negatives

• The sale price of $1.084 reflects the current low valuation of the company's equity.

Risks

• Continued reliance on equity-based compensation for key executives during periods of low share price performance.
• Market sensitivity to insider selling, even when conducted for tax purposes.

Future Outlook

The remaining 52,500 RSUs are subject to continued employment and will vest in three equal installments of 25% on the last day of each subsequent six-month period following the initial vesting.

Management Comments

• The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that insider selling for tax purposes is a standard administrative event in the biotechnology sector, particularly for companies utilizing equity-heavy compensation packages to retain talent during clinical development phases.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for biotech executives to avoid allegations of insider trading.
• The vesting schedule of two years for RSUs is consistent with standard retention practices for mid-to-senior level executives in small-cap pharmaceutical firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a pre-planned tax-related sale.

Next Steps

• Future vesting of remaining 52,500 RSUs in three equal installments.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Insider Trading, Form 4, Restricted Stock Units, Rule 10b5-1